Trastuzumab + pertuzumab + alpelisib in patients with PI3KCA-mutated, HER2-positive metastatic cancers that progressed after 4-6 cycles of taxane plus trastuzumab and pertuzumab. Here, ERBB2 is linked to metastatic malignant neoplasm.